Triple drug treatment for advanced liver cancer that can’t be removed
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older.
- Your liver cancer (HCC) has been confirmed by tumor tissue testing.
- You have not had any prior whole-body (systemic) treatment for liver cancer.
- Your cancer can’t be removed with surgery, and you either can’t get liver-directed procedures (locoregional therapy) or, if you did previously, they were finished at least 28 days before the study scan.
- Your liver function is good enough (Child-Pugh class A) and you’re active enough (ECOG 0 or 1).
- You have at least one measurable tumor spot that can be tracked on CT or MRI (size rules apply).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This study tests QL1706 together with bevacizumab and/or chemotherapy as an initial (first) treatment for advanced liver cancer. It may help shrink tumors or control the disease when surgery or local treatments aren’t suitable.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests a combination of three drugs—valemetostat, atezolizumab, and bevacizumab—for people with advanced liver cancer (HCC) who have not had systemic treatment before. The goal is to see if this combination can shrink tumors or slow disease progression.
This Phase 2 trial studies durvalumab and tremelimumab (immunotherapy medicines) in people with resectable early or intermediate-stage liver cancer (HCC). It aims to see how well these medicines work before/around the time of surgery, and whether they can improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.